Actively Recruiting

Phase 4
Age: 18Years - 85Years
All Genders
NCT06119061

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage

Led by Aaron Cook · Updated on 2025-12-26

20

Participants Needed

1

Research Sites

126 weeks

Total Duration

On this page

Sponsors

A

Aaron Cook

Lead Sponsor

C

Cumberland Pharmaceuticals

Collaborating Sponsor

AI-Summary

What this Trial Is About

The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have an in-dwelling EVD, aged 18-85 years old. Subjects will receive telavancin 10mg/kg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.

CONDITIONS

Official Title

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult aged 18-85 years
  • Actively draining ventriculostomy
Not Eligible

You will not qualify if you...

  • History of hypersensitivity to telavancin or similar agents
  • Reduced renal function (estimated creatinine clearance < 50 ml/min) at the time of consent
  • Severe anemia (hemoglobin < 7 gm/dl)
  • Vulnerable population (pregnant, prisoner)
  • Concomitant antimicrobial therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Kentucky

Lexington, Kentucky, United States, 40536

Actively Recruiting

Loading map...

Research Team

A

Aaron Cook, PharmD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here